NASDAQ:LPTX - Leap Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $4.88
Forecasted Upside: 193.67 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$1.66 As of 06/22/2021 01:00 AM ET

▼ -0.04 (-2.35%)

1 month | 3 months | 12 months

Get New Leap Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for LPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LPTX

^$4.88

▲ +193.67% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $4.88, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 193.67% upside from the last price of $1.66.

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Leap Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/30/2019

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/29/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/27/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/25/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/24/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/24/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/23/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/22/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/17/2021	Piper Sandler	Lower Price Target	Overweight	$6.00 ➝ $4.00	Low
3/23/2021	Raymond James	Set Price Target	Outperform	$3.50	Medium
3/15/2021	Raymond James	Set Price Target	Outperform	$3.50	High
3/2/2021	Raymond James	Boost Price Target	Outperform	$2.50 ➝ $3.50	High
12/23/2020	Raymond James	Set Price Target	Outperform	$2.50	N/A
11/16/2020	Raymond James	Set Price Target	Outperform	$2.50	Low
11/10/2020	Raymond James	Set Price Target	Outperform	$2.50	Low
9/22/2020	Raymond James	Set Price Target	Outperform	$2.50	Low
8/17/2020	Raymond James	Set Price Target	Outperform	$2.50	Medium
8/17/2020	HC Wainwright	Lower Price Target	Buy	$5.00 ➝ $4.00	High
7/19/2020	LADENBURG THALM/SH SH	Reiterated Rating	Market Perform ➝ Buy	$8.00	High
6/29/2020	Piper Sandler	Initiated Coverage	Overweight	$6.00	High
6/12/2020	Raymond James	Set Price Target	Outperform	$2.50	High
5/19/2020	HC Wainwright	Reiterated Rating	Buy	$2.50 ➝ $5.00	Medium
5/17/2020	Raymond James	Set Price Target	Outperform	$2.50	Medium
4/24/2020	Raymond James	Set Price Target	Outperform	$2.50	Low
3/17/2020	Raymond James	Set Price Target	Outperform	$2.50	Low
3/17/2020	HC Wainwright	Lower Price Target	Buy	$3.25 ➝ $2.50	High
2/10/2020	Robert W. Baird	Initiated Coverage	Outperform	$6.00	High
1/8/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$2.50	Low
11/15/2019	HC Wainwright	Reiterated Rating	Buy	$3.25	High
11/15/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		High
9/19/2019	Raymond James	Set Price Target	Outperform	$5.00	Low
9/13/2019	Raymond James	Initiated Coverage	Outperform	$5.00	Medium
12/19/2018	Raymond James	Lower Price Target	Outperform ➝ Outperform	$13.00 ➝ $8.00	Medium
11/13/2018	HC Wainwright	Set Price Target	Buy	$13.00	Low
10/23/2018	HC Wainwright	Set Price Target	Buy	$13.00	Medium
4/12/2018	HC Wainwright	Initiated Coverage	Buy	$12.50	Low
3/7/2017	LADENBURG THALM/SH SH	Initiated Coverage	Buy ➝ Buy	$18.00	N/A
3/1/2017	Citigroup	Initiated Coverage	Market Perform		N/A
2/28/2017	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$13.00	N/A

(Data available from 6/22/2016 forward)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Today's Range

Now: $1.66

$1.63

$1.68

50 Day Range

MA: $1.66

$1.48

$1.82

52 Week Range

Now: $1.66

$1.43

$3.24

Volume

207,871 shs

Average Volume

663,680 shs

Market Capitalization

$99.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Leap Therapeutics?

The following Wall Street analysts have issued stock ratings on Leap Therapeutics in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for LPTX.

What is the current price target for Leap Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Leap Therapeutics in the last year. Their average twelve-month price target is $4.88, suggesting a possible upside of 186.8%. LADENBURG THALM/SH SH has the highest price target set, predicting LPTX will reach $8.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $3.50 for Leap Therapeutics in the next year.
View the latest price targets for LPTX.

What is the current consensus analyst rating for Leap Therapeutics?

Leap Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LPTX will outperform the market and that investors should add to their positions of Leap Therapeutics.
View the latest ratings for LPTX.

What other companies compete with Leap Therapeutics?

Other companies that are similar to Leap Therapeutics include KemPharm, VistaGen Therapeutics, Puma Biotechnology, Foghorn Therapeutics, Verona Pharma, Cue Biopharma, DURECT, Mawson Infrastructure Group, Nature's Sunshine Products, Angion Biomedica, Terns Pharmaceuticals, 89bio, Tonix Pharmaceuticals, Kala Pharmaceuticals and MEI Pharma.

How do I contact Leap Therapeutics' investor relations team?

Leap Therapeutics' physical mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company's listed phone number is 617-714-0360 and its investor relations email address is [email protected] The official website for Leap Therapeutics is www.leaptx.com.